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Aortic insufficiency is increasingly recognized as a complication of left ventricular
assist device (LVAD) support and may lead to clinical decompensation requiring
correction. This article describes experiences in managing patients presenting with
concomitant aortic insufficiency and with de novo aortic insufficiency following left
ventricular assist device implantations.
Methods
All patients undergoing LVAD implantation between 2012 and 2014 were included
in this retrospective analysis if aortic valve insufficiency was present on
implantation or newly developed (de novo) after implantation. Moderate to severe
aortic valve insufficiency was corrected at implantation.

source are credited.

Results
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The data of 39 patients were included. At the time of LVAD implantation, moderate
to severe aortic valve insufficiency was present in 3 patients and was corrected by
bioprosthetic valve replacement (2 patients) and by bioprosthetic valve
replacement associated with ascending aorta with hemi arch replacement with a
graft due to ascending aortic aneurysm (one patient). Four patients developed
moderate to severe aortic insufficiency after LVAD surgery. Treatment with
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conservative medical management was successful in 3 patients. One patient
underwent transcatheter aortic valve occlusion using an Amplatzer closure device
after failure of medical management.
Conclusions
Concomitant aortic valve replacement with LVAD implantation is a safe and viable
option in managing aortic valve insufficiency. De novo aortic insufficiency may lead
to recurrent heart failure and presents a clinical treatment challenge following
successful LVAD support; the most appropriate and effective treatment option
awaits definition.
Keywords: aortic insufficiency, left ventricular assist device, recurrent heart failure

Introduction
The number of advanced heart failure patients treated with mechanical ventricular
assist devices for either bridge-to-transplant therapy or for permanent destination
therapy is growing.1 This expansion led to an increase in the number of patients
with concomitant valvular heart disease,2 and clinicians are now faced with
adapting treatment plans to multi-diagnosis conditions. Whereas moderate to
severe mitral valve regurgitation is common in advanced heart failure and can be
successfully treated with left ventricular assist device (LVAD) implantation,3 aortic
valve pathology, specifically moderate to severe aortic insufficiency (AI), is
uncommon at the time of LVAD implantation. Pal and colleagues reported
moderate to severe aortic insufficiency in only 4% of a series of 281 heart failure
patients.4 Several studies have described the development of AI as well as the
progression from mild AI resulting in increasing recirculation of blood volume
(closed-loop mechanism with blood flowing from the LV through the LVAD into the
aorta and back into the LV).5,6 This altered circulation path may be etiological in
the recurrence of heart failure symptoms despite LVAD implantation. This article
describes the treatment and interventions selected for heart failure patients
presenting with concomitant aortic valve insufficiency and with de novo aortic valve
insufficiency following LVAD implantations.

Methods
Medical records of all patients who underwent LVAD implantation between
October 2012 and December 2014 were extracted from the Heart Failure Data
Registry of Florida Hospital Orlando, USA, and were reviewed retrospectively. The
analysis included data of all patients with moderate to severe aortic valve
insufficiency at implantation time as well as data of all patients with normal aortic
valve function who developed aortic valve insufficiency after LVAD implantation
(de novo). Moderate or more severe AI at LVAD implantation was corrected as
recommended in the literature.5 Post-operative management included pump speed
optimization to allow for adequate aortic valve opening. Progressive and de novo
aortic regurgitation post LVAD implantation was addressed with medical
management as first-line therapy.
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Patients underwent standard pre- and intraoperative evaluation with transthoracic
and transesophageal echocardiography (TTE, TEE), left and right heart
catheterization, chest computer tomography, and pulmonary artery catheter
evaluation. Patients with postoperative new onset AI and complications were
assessed by TTE, right heart catheterization and LVAD interrogation for medical
management optimization with VAD flow adjustment, diuresis, and hypertension
control.
Due to the retrospective nature of the study ethical approval was waived by Florida
Hospital ethics committee prior to the analysis. All patients signed an informed
consent form and agreed that their data will be archived anonymously at hospital
and national data registries (e.g. INTERMACS)

Results
Data of 39 patients (21-76 years of age, 13% female, 23% bridge-to-transplant,
77% destination therapy) were included in this retrospective analysis. Overall,
patient 1-year survival was 89% with bridge-to-transplant VADs and 75% with
destination VADs.
Intraoperative TEE assessments revealed moderate to 2+ AI in three patients with
a history of dilated cardiomyopathy (patients 1-3, Table 1). Two patients were
considered for destination therapy and one patient was listed and bridged to heart
transplantation. The destination therapy patients (patients 1 and 2) underwent
bioprosthetic aortic valve replacement (21 and 23 mm standard CarpentierEdwards bioprosthetic valves [Edwards Lifesciences Corporation, Irvine, CA,
USA]) combined with HeartMate II implantation (HM II; Thoratec Corporation,
Pleasanton, CA, USA). They were connected to cardiopulmonary bypass through
standard distal ascending aorta and right atrial cannulation and cooled down to 34°
C. After LVAD implantation, a short period of antegrade hypothermic crystalloid
arrest after aorta cross-clamping allowed standard aortic valve replacement
through a hockey stick-like aortotomy 1.5 cm distal to the origin of the right
coronary artery. After release of the cross-clamp and reperfusion of the heart, the
outflow graft was trimmed to its appropriate length and sutured end-to-side to the
ascending aorta using a partial occlusion clamp. The third patient presented with
moderate AI and severe ascending aortic dilatation to 52 mm with a very thin aortic
wall (patient 3). He underwent a relatively complex procedure consisting of aortic
bioprosthetic valve replacement (Carpentier-Edwards bioprosthetic valve) with
ascending and hemi aortic arch replacement using circulatory arrest together with
LVAD implantation. The surgical strategy was similar as described for the two
destination therapy patients followed by hemi arch replacement using deep
hypothermic circulatory arrest and 30 mm tube graft prosthesis with a single
sidearm. The LVAD outflow graft was sutured end-to-end to the sidearm of the
vascular prosthesis. All three patients made an uneventful recovery and were
monitored monthly with TTE in the program affiliated clinics. There were no
complications related to the prosthetic aortic valve such as thrombosis, stroke, or
valve degeneration. All three patients survived the first year following LVAD
implantation.
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Table 1. Patients with end-stage cardiomyopathy treated using aortic valve
replacement and left ventricular assist devices
Patient

Gender

Age
(years)

Cardiomyopathy

Procedure/d
evice

Type of
therapy

Diagnosis of aortic
insufficiency

Medical
manageme
nt of aortic
insufficienc
y

1

Male

70

Dilative

AVR/HM II

DT

Time of implant

No

2

Male

68

Dilative

AVR/HM II

DT

Time of implant

No

3

Male

56

Dilative

Complex
AVR/HVAD

BTT

Time of implant

No

4

Female

64

Dilative

HM II

DT

8 months

Yes

postoperative
5

Male

70

Ischemic

HM II

DT

8 months

Yes

postoperative
6

Male

58

Dilative

HVAD

BTT

8 months
postoperative

7

Male

74

Ischemic

HM II

DT

8 months
postoperative

Yes +
Heart
transplant
Yes +
Amplatzer
device

AVR, aortic valve replacement; BTT, bridge-to-transplant; DT, destination therapy;
HM, Heartmate; HVAD, HeartWare

Eight months following LVAD implantation, four patients (patients 4-7, Table 1)
presented with heart failure and AI onset (3 patients on HM II, one patient on
HeartWare HVAD [HeartWare, Framingham, MA, USA]). Heart failure was
recurrent and was attributable to the newly developed AI. The initial management
was conservative with medical treatment including diuretics and vasodilators but
also TTE-controlled LVAD interrogation, LVAD flow reduction through a decrease
in pump speed until frequent aortic valve opening was documented. These
conservative measures were successful in two of the four patients (patients 4 and
5). The condition of the third patient (patient 6) deteriorated 14 months after an
initial positive response to medical treatment and LVAD flow adjustments; he
underwent orthotopic heart transplantation which was successful. In the fourth
patient (patient 7), left-sided symptoms persisted and worsening shortness of
breath was observed. Eleven months after HM II implantation as third-time
The VAD Journal: https://doi.org/10.13023/VAD.2018.03

Page 4 of 8

The VAD Journal: The journal of mechanical assisted circulation and heart failure

sternotomy for ischemic cardiomyopathy he presented with severe right and left
heart failure, multiorgan dysfunction, and hepatorenal failure. De novo AI and
clinical decompensation were diagnosed. A decrease of HM II flow through
reducing RPM from 8800 RPM to 8200 RPM markedly attenuated the AI but
medical optimization management was not successful. The patient required
inotropic medications and mechanical ventilatory support for worsening right heart
failure and pulmonary edema. Immediate pre-procedure hemodynamics were right
arterial pressure 17 mmHg, pulmonary artery pressure 54/32 mmHg, pulmonary
artery occlusion pressure 22 mmHg, left ventricular pressure 90/50 mmHg, left
ventricular end-diastolic pressure 20 mmHg, and cardiac output 2.4 L/min.
Ultimately, the patient underwent percutaneous transcatheter closure of the aortic
valve with a multi fenestrated 30 mm Amplatzer Cribriform (AGA Medical Corp,
Plymouth, MN, USA) closure device (reported as a case report7). Immediate postprocedure hemodynamics were right arterial pressure 3 mmHg, pulmonary artery
pressure 32/14 mmHg, pulmonary artery occlusion pressure 16 mmHg.
Fluoroscopy and TTE confirmed the successful aortic valve closure. Under
echocardiography, the LVAD flow was increased to 9400 RPM. Two weeks after
the procedure, the patient remained stable with improved symptoms and functional
status and without evidence of further AI or device migration. The patient was
discharged after 34 days of rehabilitation and nutritional support and was
monitored closely by the heart failure team. He did not achieve the same exercise
tolerance level as observed before aortic valve closure. The patient expired 14
months after LVAD implantation in a hospice following a fall and head trauma
associated with intracranial bleeding.

Discussion
Aortic stenosis or insufficiency is uncommon in patients with advanced heart
failure considered for LVAD implantation.4 The main concern lies in the initiation of
LVAD support which can exacerbate pre-existing AI.8,9 It was suggested that LVAD
implantations create a continuous transvalvular pressure gradient (aortic pressure
over LV pressure) across the aortic valve leading to rare aortic valve openings
throughout the cardiac cycle. This may lead to fibrous tissue deposits along the
commissures of the leaflets, resulting in leaflet adherence, fusion, and retraction of
the leaflet tips and generation of a central orifice.10 A closed aortic valve and
limited antegrade blood flow can lead to stasis on the ventricular surface of the
aortic valve generating thrombus formation and organization which further
aggravates leaflet fusion.8,10 The transvalvular pressure gradient described above
can result in regurgitant flow from aorta to LV through the central orifice.
Pathophysiologically, this recirculating blood volume may result in the recurrence
of heart failure symptoms. Given the potential for AI to progress after LVAD
insertion, all moderate or greater degrees of AI at the time of implantation were
corrected. Three patients successfully underwent concomitant bioprosthetic aortic
valve replacement at the time of LVAD implantation. We are not in favor of LV
outflow tract closure techniques such as coaptation stitches of the leaflet tips,
buttressing stitches of the commissures, or a sutured circular patch or membrane
plug technique. Although these simple repair techniques require a shorter period of
cardioplegic arrest, they are limited, because they complicate cardiovascular
support measures in case of device malfunction and pump failure. Furthermore, a
subset of advanced heart failure patients unloaded by LVAD may experience a
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return of cardiac function and become candidates for device weaning and
explantation.11 We favor bioprosthetic aortic valve replacement as the treatment of
choice for moderate or more severe AI given its low complication risks and reliable
results and agree with the view that aortic valve provides a “bail-out” mechanism
should acute LVAD malfunction occur.5 A subgroup analysis revealed a markedly
lower long-term survival of patients undergoing LVAD and isolated aortic valve
procedures, however, these patients were significantly sicker, older, and with
increased right ventricular dysfunction.12 After multivariate adjustments, surgical
aortic valve closure was associated with increased mortality when compared with
aortic valve replacement in patient with AI who underwent LVAD insertion.13
The development of aortic insufficiency was noted in 25% to 52% of patients by 1
year of LVAD support.5 Thirty-six of 166 patients supported by LVAD for a median
461 days developed moderate AI at a median 273 days after LVAD implantation.6
AI development was more pronounced in continuous-flow compared with pulsatileflow LVAD.14 Newly developed AI after LVAD implantation affects device
performance, leads to recurrent heart failure symptomatology, and impacts patient
outcomes. In our series of heart failure patients supported by LVAD, de novo AI
occurred in four patients in close follow-up ambulatory studies over an average of
8 months. Serial echocardiography revealed intermittent aortic valve opening and
pulsatile flow. First-line treatment included diuretics and oral vasodilators to control
hypertension and to reduce gradients driving aortic valve insufficiency.
Additionally, the selected pump speed setting was adjusted by echocardiography
guidance to ensure sufficient circulatory support at rest while allowing intermittent
aortic valve opening and maintaining normal LV dimensions. Three of the four
patients showed a mild degree of LV myocardial recovery on echocardiography
and associated increased ejection and pulsatility allowing a reduction in pump
speed.
Clinically significant de novo AI refractory to medical management and LVAD flow
optimization is best treated with surgical AI correction or heart transplantation. In
cases where conventional aortic valve replacement was of very high risk,
percutaneous transcatheter aortic valve closure has been previously described in
5 LVAD patients with de novo AI.15 The authors concluded that percutaneous
transcatheter closure (if successfully employed) appears to be a safe and effective
method to treat AI in patients with LVAD, a population often too sick to undergo
reoperation for treatment. Although the results are encouraging, the technique
needs to be studied in a larger cohort for long-term follow-up. The transcatheter
aortic valve replacement might be another good option for these patients with de
novo AI; it is, however, not yet approved by the Food and Drug Administration for
AI.
In summary, concomitant aortic valve surgery with LVAD implantation is safe and
associated with a good outcome. De novo aortic insufficiency and regurgitation
may lead to recurrent heart failure and remains a clinical treatment challenge
following successful LVAD implantation and support. Most of the patient with de
novo AI will respond to optimized medical therapy; the most appropriate and
effective treatment option awaits definition.
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